Compared to controls, HPV+PFPS+DCs significantly inhibited tumor growth in both the early and late phases, which was significantly associated with an elevated activation status of CD4+ and CD8+ T cells, suggesting that PFPS may be a potential adjuvant for the DC vaccine. Here, CD4 is linked to neoplasm.